Literature DB >> 24413406

Prospective nationwide surveillance of hospitalizations due to pertussis in children, 2006-2010.

Ulrich Heininger1, Daniel Weibel, Jean-Luc Richard.   

Abstract

BACKGROUND: Frequency of pertussis is highly variable from country to country and it depends on multiple factors including case definitions and type of surveillance systems used. Many countries recently reported an increase of pertussis cases especially in infants and adolescents.
METHODS: From April 2006 to March 2011, 15-year-old patients hospitalized with suspected or proven pertussis were reported to the Swiss Pediatric Surveillance Unit. Patients with ≥14 days of cough plus paroxysms, whooping or post-tussive vomiting fulfilled the clinical case definition of pertussis. For laboratory confirmation, Bordetella pertussis polymerase chain reaction was offered free of charge.
RESULTS: Data were available from 159 of 173 reported cases and 130 (90% of them <12 months old) were eligible including 125 laboratory-confirmed B. pertussis infections. Rates per 100,000 population were 2.6 (<16 years) and 38.8 (<12 months), respectively. Most frequent complications were cyanosis (63%) and sleep disturbance (60%); 35 (27%) patients received intensive care and 1 patient died. Source of infection was known in 79 (61%) patients and was mainly a sibling, parent or both. Most patients were unimmunized (65%) or incompletely immunized (30%).
CONCLUSIONS: The high rate of pertussis hospitalization in young infants established in this surveillance project and the incomplete pertussis immunization status in almost all hospitalized patients require further efforts for improvement. In addition, introduction of pertussis immunizations for all adolescents (in 2013), young adults (in 2012) and pregnant women (in 2013) in Switzerland should increase indirect protection of vulnerable newborns and infants too young to be fully immunized.

Entities:  

Mesh:

Year:  2014        PMID: 24413406     DOI: 10.1097/01.inf.0000435503.44620.74

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

1.  Caffeine to prevent respiratory failure and improve outcome in infant pertussis.

Authors:  John Evered; Eric Pfeifer; Matthew Gracianette
Journal:  BMJ Case Rep       Date:  2018-03-28

2.  Clinical characteristics of pediatric pertussis cases, Quebec 2015-2017.

Authors:  M Desjardins; D Iachimov; S Mousseau; P Doyon-Plourde; N Brousseau; F Rallu; C Quach
Journal:  Can Commun Dis Rep       Date:  2018-09-06

3.  Risk factors and prediction model of severe pertussis in infants < 12 months of age in Tianjin, China.

Authors:  Cui Zhang; Yanmei Zong; Ying Li; Yuejie Yang; Zhe Wang; Li Wang
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

4.  Protecting newborns from pertussis - the challenge of complete cocooning.

Authors:  Pascal Urwyler; Ulrich Heininger
Journal:  BMC Infect Dis       Date:  2014-07-17       Impact factor: 3.090

5.  Intention to Accept Pertussis Vaccination for Cocooning: A Qualitative Study of the Determinants.

Authors:  Olga Visser; Jeannine L A Hautvast; Koos van der Velden; Marlies E J L Hulscher
Journal:  PLoS One       Date:  2016-06-02       Impact factor: 3.240

6.  Child-parent immunization survey: How well are national immunization recommendations accepted by the target groups?

Authors:  M L Erb; T E Erlanger; U Heininger
Journal:  Vaccine X       Date:  2019-03-01

7.  The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a systematic review and meta-analysis.

Authors:  Rudzani Muloiwa; Benjamin M Kagina; Mark E Engel; Gregory D Hussey
Journal:  BMC Med       Date:  2020-08-28       Impact factor: 8.775

8.  Risk factors for Bordetella pertussis disease in hospitalized children.

Authors:  Rudzani Muloiwa; Felix S Dube; Mark P Nicol; Gregory D Hussey; Heather J Zar
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.